WO2004007682A3 - Methods and compositions for modulating t helper (th) cell development and function - Google Patents

Methods and compositions for modulating t helper (th) cell development and function Download PDF

Info

Publication number
WO2004007682A3
WO2004007682A3 PCT/US2003/021975 US0321975W WO2004007682A3 WO 2004007682 A3 WO2004007682 A3 WO 2004007682A3 US 0321975 W US0321975 W US 0321975W WO 2004007682 A3 WO2004007682 A3 WO 2004007682A3
Authority
WO
WIPO (PCT)
Prior art keywords
helper
modulating
compositions
methods
function
Prior art date
Application number
PCT/US2003/021975
Other languages
French (fr)
Other versions
WO2004007682A2 (en
Inventor
Michael Grusby
Andrea Wurster
Deborah A Young
Mary Collins
Matthew J Whitters
Original Assignee
Wyeth Corp
Harvard College
Michael Grusby
Andrea Wurster
Deborah A Young
Mary Collins
Matthew J Whitters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA05000655A priority Critical patent/MXPA05000655A/en
Priority to EP03764624A priority patent/EP1553982A4/en
Priority to JP2004521793A priority patent/JP4776228B2/en
Priority to EA200500206A priority patent/EA011686B1/en
Priority to CA002491320A priority patent/CA2491320A1/en
Priority to AU2003251900A priority patent/AU2003251900B2/en
Application filed by Wyeth Corp, Harvard College, Michael Grusby, Andrea Wurster, Deborah A Young, Mary Collins, Matthew J Whitters filed Critical Wyeth Corp
Priority to BRPI0312738-9A priority patent/BR0312738A/en
Publication of WO2004007682A2 publication Critical patent/WO2004007682A2/en
Priority to IL16599004A priority patent/IL165990A0/en
Publication of WO2004007682A3 publication Critical patent/WO2004007682A3/en
Priority to NO20050717A priority patent/NO20050717L/en
Priority to IL195769A priority patent/IL195769A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Abstract

Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
PCT/US2003/021975 2002-07-15 2003-07-15 Methods and compositions for modulating t helper (th) cell development and function WO2004007682A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP03764624A EP1553982A4 (en) 2002-07-15 2003-07-15 METHODS AND COMPOSITIONS FOR MODULATING T HELPER (T sb H /sb ) CELL DEVELOPMENT AND FUNCTION
JP2004521793A JP4776228B2 (en) 2002-07-15 2003-07-15 Methods and compositions for modulating the development and function of T helper (TH) cells
EA200500206A EA011686B1 (en) 2002-07-15 2003-07-15 Method for modulating t helper (t) cell development
CA002491320A CA2491320A1 (en) 2002-07-15 2003-07-15 Methods and compositions for modulating t helper (th) cell development and function
AU2003251900A AU2003251900B2 (en) 2002-07-15 2003-07-15 Methods and compositions for modulating T helper (Th) cell development and function
MXPA05000655A MXPA05000655A (en) 2002-07-15 2003-07-15 Methods and compositions for modulating t helper (th.
BRPI0312738-9A BR0312738A (en) 2002-07-15 2003-07-15 processes and compositions for modulating helper t cell development and function (th)
IL16599004A IL165990A0 (en) 2002-07-15 2004-12-26 Methods and compositions for modulating T helper (TH) cell development and function
NO20050717A NO20050717L (en) 2002-07-15 2005-02-10 Method and compositions for modulating T helper (TH) cell development and function
IL195769A IL195769A0 (en) 2002-07-15 2008-12-07 Methods and compositions for modulating t helper (th) cell development and function

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39616002P 2002-07-15 2002-07-15
US60/396,160 2002-07-15
US40300102P 2002-08-12 2002-08-12
US60/403,001 2002-08-12

Publications (2)

Publication Number Publication Date
WO2004007682A2 WO2004007682A2 (en) 2004-01-22
WO2004007682A3 true WO2004007682A3 (en) 2004-12-29

Family

ID=30118569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021975 WO2004007682A2 (en) 2002-07-15 2003-07-15 Methods and compositions for modulating t helper (th) cell development and function

Country Status (14)

Country Link
US (2) US7314623B2 (en)
EP (1) EP1553982A4 (en)
JP (2) JP4776228B2 (en)
KR (1) KR20050037552A (en)
CN (1) CN1688340A (en)
AU (1) AU2003251900B2 (en)
BR (1) BR0312738A (en)
CA (1) CA2491320A1 (en)
EA (1) EA011686B1 (en)
IL (2) IL165990A0 (en)
MX (1) MXPA05000655A (en)
NO (1) NO20050717L (en)
WO (1) WO2004007682A2 (en)
ZA (1) ZA200500480B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP2377549A1 (en) 2002-06-07 2011-10-19 ZymoGenetics, Inc. Use of IL-21 for treating viral infections
BR0312738A (en) 2002-07-15 2007-06-26 Wyeth Corp processes and compositions for modulating helper t cell development and function (th)
JP4914209B2 (en) 2003-03-14 2012-04-11 ワイス Antibody against human IL-21 receptor and use of the antibody
KR20060015482A (en) * 2003-03-21 2006-02-17 와이어쓰 Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
WO2005030196A2 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
WO2005035565A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
BRPI0514138A (en) * 2004-08-05 2008-05-27 Wyeth Corp method for treating, ameliorating, or preventing a disorder, fusion protein, vector, recombinant host cell, method for producing a fusion protein, pharmaceutical composition, and methods for transplanting / grafting an organ, tissue, cell or cell group into a mammalian individual, and to treat, prevent or ameliorate transplant / graft rejection in a mammalian transplant / graft recipient
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
EP2567973B1 (en) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
US7592427B2 (en) * 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
ES2547689T3 (en) * 2005-12-02 2015-10-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling that involve antibodies that bind to IL-22 and IL-22R
KR101615215B1 (en) 2007-12-07 2016-04-25 지모제넥틱스, 인코포레이티드 Anti-human il-21 monoclonal antibodies
EP2238241B1 (en) 2008-01-18 2013-09-11 The Brigham and Women's Hospital, Inc. Selective differentiation, identification, and modulation of human th17 cells
AR071885A1 (en) * 2008-05-23 2010-07-21 Wyeth Corp PROTEINS OF UNION TO THE INTERLEUQUINE RECEIVER 21
EP2296689A1 (en) * 2008-05-23 2011-03-23 Wyeth LLC Methods of treatment utilizing binding proteins of the interleukin-21 receptor
MX2020004501A (en) 2010-06-03 2021-11-09 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk).
WO2012099886A1 (en) 2011-01-18 2012-07-26 Bioniz, Llc Compositions and mehthods for modulating gamma-c-cytokine activity
US9920932B2 (en) 2011-01-26 2018-03-20 United Technologies Corporation Mixer assembly for a gas turbine engine
KR20130011056A (en) * 2011-07-20 2013-01-30 주식회사에이앤알쎄라퓨틱스 Receptors targeting inflammation and drug carriers for treatment of inflammatory diseases
BR112015001690A2 (en) 2012-07-24 2017-11-07 Pharmacyclics Inc mutations associated with resistance to bruton tyrosine kinase inhibitors (btk)
WO2014071231A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
RS58187B1 (en) 2012-11-08 2019-03-29 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
US20140170727A1 (en) * 2012-12-19 2014-06-19 Nanomr, Inc. Affinity medium using fixed whole cells
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
JP6863974B2 (en) 2015-10-09 2021-04-21 バイオニズ リミテッド ライアビリティー カンパニー Regulation of γc cytokine activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
EP0325224B1 (en) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5216131A (en) * 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5098833A (en) * 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) * 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ATE381614T1 (en) 1992-07-24 2008-01-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2742156A1 (en) 1995-12-06 1997-06-13 Sanofi Sa IL-13 RECEPTOR POLYPEPTIDE
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU2326097A (en) 1996-03-13 1997-10-01 Zymogenetics Inc. Cytokine-receptor expressed in testis cells
EP0812913A3 (en) 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1997047741A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
AUPO224696A0 (en) 1996-09-11 1996-10-03 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP2001508309A (en) 1997-01-16 2001-06-26 ジェネティックス・インスチチュート・インコーポレーテッド Member of the hematopoietin receptor superfamily
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1088831A4 (en) 1998-06-24 2003-01-02 Chugai Pharmaceutical Co Ltd Novel hemopoietin receptor proteins
AU5104799A (en) 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
EA201001190A1 (en) 1998-09-23 2011-04-29 Займодженетикс, Инк. ISOLATED ANTIBODY, SPECIFICALLY ASSOCIATED WITH POLYPEPTIDE, CONTAINING FROM THE SEQUENCE OF AMINO ACID RESIDUES
EP1124851A1 (en) 1998-11-06 2001-08-22 Smithkline Beecham Corporation Hnovilr
CN101575377B (en) 1999-03-09 2012-12-26 津莫吉尼蒂克斯公司 Human cytokine as ligand of zalpha receptor and use thereof
US20020090680A1 (en) 1999-05-18 2002-07-11 Millennium Pharmaceuticals, Inc. Novel IL-9/IL-2 receptor-like molecules and uses thereof
DE60141234D1 (en) 2000-04-05 2010-03-18 Zymogenetics Inc Soluble cytokine receptor zalpfa11
DE60124954T2 (en) 2000-05-11 2007-09-20 Genetics Institute, LLC, Cambridge MU-1, A MEMBER OF THE CYTOKINE RECEPTOR FAMILY
DE60125563T2 (en) * 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis METHOD FOR USE OF A HUMAN IL-17 RELATED POLYPEPTIDE FOR THE TREATMENT OF DISEASES
JP2005508915A (en) * 2001-10-04 2005-04-07 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Methods and compositions for modulating interleukin 21 receptor activity
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
BR0312738A (en) 2002-07-15 2007-06-26 Wyeth Corp processes and compositions for modulating helper t cell development and function (th)
JP4914209B2 (en) 2003-03-14 2012-04-11 ワイス Antibody against human IL-21 receptor and use of the antibody
KR20060015482A (en) 2003-03-21 2006-02-17 와이어쓰 Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
AU2005244942A1 (en) 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
BRPI0514138A (en) 2004-08-05 2008-05-27 Wyeth Corp method for treating, ameliorating, or preventing a disorder, fusion protein, vector, recombinant host cell, method for producing a fusion protein, pharmaceutical composition, and methods for transplanting / grafting an organ, tissue, cell or cell group into a mammalian individual, and to treat, prevent or ameliorate transplant / graft rejection in a mammalian transplant / graft recipient
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand

Also Published As

Publication number Publication date
ZA200500480B (en) 2006-10-25
CN1688340A (en) 2005-10-26
WO2004007682A2 (en) 2004-01-22
MXPA05000655A (en) 2006-02-22
US7731946B2 (en) 2010-06-08
IL195769A0 (en) 2009-09-01
US20040136954A1 (en) 2004-07-15
EP1553982A4 (en) 2008-03-26
IL165990A0 (en) 2006-01-15
BR0312738A (en) 2007-06-26
JP2010090133A (en) 2010-04-22
KR20050037552A (en) 2005-04-22
JP4776228B2 (en) 2011-09-21
AU2003251900A1 (en) 2004-02-02
CA2491320A1 (en) 2004-01-22
AU2003251900B2 (en) 2008-12-18
US7314623B2 (en) 2008-01-01
JP2006507231A (en) 2006-03-02
EA200500206A1 (en) 2006-06-30
EP1553982A2 (en) 2005-07-20
EA011686B1 (en) 2009-04-28
US20090197803A1 (en) 2009-08-06
NO20050717L (en) 2005-04-11

Similar Documents

Publication Publication Date Title
WO2004007682A3 (en) Methods and compositions for modulating t helper (th) cell development and function
WO2001083755A3 (en) Human anti-cd40 antibodies and methods of making and using same
WO2003000038A3 (en) Compositions and methods for modulating plant development
WO2004045455A3 (en) Deformable bone plates
WO2005069865A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2002099052A3 (en) Opns as modifiers of the p53 pathway and methods of use
WO2006036994A3 (en) Modulators of crth2, cox-2 and faah
WO2006042206A3 (en) Systems and methods for direct restoration of foraminal volume
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU2003230834A1 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
WO2005023305A3 (en) Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
WO2006042173A3 (en) Modulators of hepatocyte growth factor activator
AU2003270705A1 (en) Compounds containing silicon-containing groups, medical devices, and methods
WO2003014299A3 (en) SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003263788A1 (en) Educational prosthesis device and method for using the same
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU2003285296A1 (en) Coumpounds modulating the activity of gapdh and/or iamt
AU2003287521A1 (en) Pluripotent cells from monocytes, and methods of making and using pluripotent cells
WO2005115456A3 (en) METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY
WO2004003152A3 (en) Sos1 inhibitors
AU2003217942A1 (en) Modulators of leukocyte activation, compositions, and methods of use
WO2005055942A3 (en) Modulation of brain pathways and function
EP1706123A4 (en) Compositions derived from portulaca oleracea l. and methods of using same for modulating blood glucose levels
WO2003062197A3 (en) Nek2 inhibitors
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 165990

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2491320

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 56/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000655

Country of ref document: MX

Ref document number: 537673

Country of ref document: NZ

Ref document number: 1-2005-500106

Country of ref document: PH

Ref document number: 1020057000735

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038169150

Country of ref document: CN

Ref document number: 2004521793

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005/00480

Country of ref document: ZA

Ref document number: 200500480

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 05009447

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1200500160

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2003251900

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003764624

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200500206

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020057000735

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003764624

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0312738

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 12008502024

Country of ref document: PH